A next-generation approach to NASH clinical trials uses anonymized EHR and claims data, non-invasive diagnostics, and innovative site models. This can help you speed recruitment, optimize sites, shorten timelines and cut development costs.
Attend this live webinar and learn how QuintilesIMS can help you achieve your goals in developing your NASH treatment.
Mark H. Delegge, MD
Senior Medical Director, QuintilesIMS
VP CRO/Life Science, Perspectum Diagnostics